Insider · CIK 0001831755
Michael LaCascia
Files at FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.
In brief
Michael LaCascia files SEC Form 4 as officer at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael LaCascia has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock option (right to buy)derivative | +295,000 | $5.71 | $1.7M | 295,000 | Feb 2, 2026 |
| Jan 22, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +126,000 | $4.37 | $551k | 126,000 | Jan 24, 2025 |
Questions about Michael LaCascia
Answered from the filings on this page, as of the latest one.
Is Michael LaCascia buying or selling?
Michael LaCascia has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael LaCascia's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael LaCascia has 0.
Where does Michael LaCascia file Form 4?
Michael LaCascia has filed Form 4 at FHTX (Foghorn Therapeutics Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.